UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stake in Avanos Medical, Inc. $AVNS

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in shares of Avanos Medical, Inc. (NYSE:AVNS) by 29.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 147,266 shares of the company’s stock after selling 62,894 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.31% of Avanos Medical worth $3,664,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Federated Hermes Inc. lifted its stake in shares of Avanos Medical by 2.8% in the fourth quarter. Federated Hermes Inc. now owns 25,774 shares of the company’s stock worth $289,000 after buying an additional 691 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Avanos Medical by 15.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 6,317 shares of the company’s stock valued at $89,000 after acquiring an additional 846 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Avanos Medical by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock valued at $386,000 after acquiring an additional 1,121 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Avanos Medical by 132.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock valued at $28,000 after acquiring an additional 1,423 shares during the last quarter. Finally, Swiss National Bank lifted its stake in Avanos Medical by 2.1% in the 4th quarter. Swiss National Bank now owns 91,500 shares of the company’s stock worth $1,028,000 after purchasing an additional 1,900 shares in the last quarter. 95.17% of the stock is currently owned by institutional investors and hedge funds.

Avanos Medical Stock Performance

NYSE:AVNS opened at $24.99 on Thursday. The company’s 50-day moving average is $24.98 and its two-hundred day moving average is $22.01. Avanos Medical, Inc. has a 1-year low of $9.30 and a 1-year high of $25.49. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.48 and a quick ratio of 1.40. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -15.52 and a beta of 1.57.

Analyst Upgrades and Downgrades

AVNS has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, July 20th. Zacks Research upgraded Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Friday, June 5th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.